Document Detail


Cerebrolysin therapy in Rett syndrome: clinical and EEG mapping study.
MedLine Citation:
PMID:  11738849     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Based on the suggestion that nerve growth factor plays a core role in the brain maturation process, which is altered in Rett syndrome, we investigate the influence of Cerebrolysin--the brain-derived peptidergic drug - on motor and higher cortical functions in Rett syndrome girls. The open pilot study was performed on nine Rett syndrome girls (aged from 2 years and 2 months to 7 years and 6 months) at stage 3 of the illness, and included both clinical and quantitative EEG evaluations before and after Cerebrolysin treatment. After Cerebrolysin treatment, increases in the behavioral activity, attention level, motor functions, and non-verbal social communication have been shown in Rett syndrome patients. EEG parameters after Cerebrolysin treatment also changed towards normal values, indicating an improvement of the brain functional state. EEG changes included: decrease of theta activity over all cortical regions, increase of beta activity in the frequency band 13-15 Hz, and some restoration of the occipital alpha rhythm (in the narrow 8-9 Hz band). The data obtained suggested possible perspectives of Cerebrolysin in complex therapy of Rett syndrome.
Authors:
N Gorbachevskaya; V Bashina; V Gratchev; A Iznak
Related Documents :
15589059 - Chemokine profile in the cerebrospinal fluid and serum of vogt-koyanagi-harada disease.
9118829 - Brachycephaly is ineffective for detection of down syndrome in early midtrimester fetuses.
19648639 - Prevalence of postweaning multisystemic wasting syndrome in pigs sired by 13 hungarian ...
11578999 - Neuroanatomy of down's syndrome: a high-resolution mri study.
16797399 - A rare case of combined syndrome of inappropriate antidiuretic hormone secretion and fa...
20466299 - Ventriculomegaly, intrauterine growth restriction, and congenital heart defects as sali...
24774729 - Magnitude and management of metabolic syndrome in spain in 2008-2010: the enrica study.
2925929 - Pulmonary ct findings in behçet disease.
22349879 - Entheseal ultrasound abnormalities in patients with sapho syndrome.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Brain & development     Volume:  23 Suppl 1     ISSN:  0387-7604     ISO Abbreviation:  Brain Dev.     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2001-12-18     Completed Date:  2002-03-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7909235     Medline TA:  Brain Dev     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  S90-3     Citation Subset:  IM    
Affiliation:
Menial Health Research Centre, 115522, Moscow, Russia. gorbachevskaya@aport2000.ru
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acids / therapeutic use*
Cerebral Cortex / drug effects*,  growth & development,  physiopathology
Child
Child, Preschool
Electroencephalography / drug effects*
Female
Humans
Movement Disorders / drug therapy
Nerve Growth Factor / analogs & derivatives*,  metabolism
Neuroprotective Agents / therapeutic use*
Pilot Projects
Recovery of Function / drug effects*,  physiology
Rett Syndrome / drug therapy*,  physiopathology
Social Behavior Disorders / drug therapy
Speech Disorders / drug therapy
Treatment Outcome
Chemical
Reg. No./Substance:
0/Amino Acids; 0/Neuroprotective Agents; 12656-61-0/cerebrolysin; 9061-61-4/Nerve Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Medium-term open label trial of L-carnitine in Rett syndrome.
Next Document:  Pathophysiology of Rett syndrome from the stand point of clinical characteristics.